Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | SVP, Finance and Treasurer | October 01, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date October 01, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 50,984 |
Reported balance
After 2026-10-01 transaction · row 1
1 source rowRow 1 · 2026-10-01 · Sale · Disposed 187 · Balance 50,984 F1: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 01, 2026 Filed Oct 3, 2026 00:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 187 | $24.41 | $4,564.67 |
DisclosureSEC source: 0001193125-26-412236 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,984 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024. Read SEC document |
| April 01, 2026 Filed Apr 6, 2026 21:39 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,242 | $24.58 | $79,688.36 |
DisclosureSEC source: 0001193125-26-144068 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,171 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:22 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-140553 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,813 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $27.62 | $0.00 |
DisclosureSEC source: 0001193125-26-033605 · ownership.xml · derivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-31 F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,198 | $35.00 | $216,933.10 |
DisclosureSEC source: 0001193125-26-022563 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,813 F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 19, 2025. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $35.00 to $35.015, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| January 20, 2026 Filed Jan 21, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,034 | $30.12 | $91,384.08 |
DisclosureSEC source: 0001193125-26-017942 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 41,011 F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 19, 2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:15 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 467 | $24.53 | $11,455.51 |
DisclosureSEC source: 0001193125-25-230195 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,045 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on September 30, 2021 and September 30, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 01:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,015 | $18.35 | $55,330.07 |
DisclosureSEC source: 0000950170-25-050855 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,512 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 9, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:11 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-049761 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,527 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| February 18, 2025 Filed Feb 20, 2025 21:10 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,287 | $35.00 | $220,045.00 |
DisclosureSEC source: 0000950170-25-024149 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,527 F1 · kind: The shares of Common Stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 18, 2024. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0000950170-25-012303 · ownership.xml · derivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-01-31 F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| January 02, 2025 Filed Jan 6, 2025 22:48 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,117 | $24.68 | $27,567.56 |
DisclosureSEC source: 0000950170-25-002355 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,814 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Peerson in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on December 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $24.21 to $25.02, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 01, 2024 Filed Oct 2, 2024 21:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 289 | $23.48 | $6,785.46 |
DisclosureSEC source: 0000950170-24-111737 · ownership.xml · nonDerivative · entry 2 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,931 F2 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain RSUs granted to the Reporting Person under the Plan on September 30, 2021. These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $23.45 to $23.48, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 30, 2024 Filed Oct 2, 2024 21:51 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-111737 · ownership.xml · nonDerivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,220 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan (the "Plan"). Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| August 31, 2024 Filed Sep 3, 2024 20:15 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $26.68 | $0.00 |
DisclosureSEC source: 0000950170-24-102823 · ownership.xml · derivative · entry 1 Cavanagh Bethany J · CIK 0002033155 · SVP, Finance and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2034-08-31 F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.